, Volume 117, Issue 1, pp 110–115

Nicotine intake in smokers increases following a single dose of haloperidol

  • S. Dawe
  • J. A. Gray
  • M. A. H. Russell
  • C. Gerda
Original Investigation


The effects of oral haloperidol on nicotine intake, subjective measures of craving and smoking satisfaction were compared with placebo in light-to-moderate smokers from a post-prandial cigarette and during the subsequent hour of unrestricted smoking. Subjects smoked significantly more, as measured by blood nicotine levels, when they had received haloperidol, although there was no difference between haloperidol and placebo an any subjective measures. These findings may be interpreted to reflect a compensatory increase in smoking in order to obtain the usual nicotine reward. Having achieved usual levels of reward, subjects did not experience a decrease in subjective measures of smoking satisfaction or an increase in nicotine craving.

Key words

Nicotine Haloperidol Drug reward Craving Human subjects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson BG, Reker D, Cooper TB (1981) Prolonged adverse effects of haloperidol in normal subjects. N Engl J Med 11:643–644Google Scholar
  2. Baldessarini RJ (1985) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman L, Rall TW, Murad F (eds) Goodman and Gilman's The pharmacological basis of therapeutics. Macmillan NewYorkGoogle Scholar
  3. Baxter LR, Schwartz JM, Phelps M, Mazziotta J, Barrio J, Rawson R, Engel J, Guze B, Selin C, Sumida R (1988) Localisation of neurochemical effects of cocaine and other stimulants in the human brain. J Clin Psychol 49:23–26Google Scholar
  4. Benowitz NL, Porchet H, Jacob P (1990) Pharmacokinetics, metabolism and pharmacodynamics of nicotine. In: Wonnacott S, Russell, MAH, Stolerman IP (eds) Nicotine psychopharmacology: molecular, cellular and behavioural aspects. Oxford University Press, OxfordGoogle Scholar
  5. Brazell MP, Mitchell SN, Joseph MH, Gray JA (1990) Acute administration of nicotine increases thein vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate putamen. Neuropharmacology 29:1177–1185CrossRefPubMedGoogle Scholar
  6. Corrigall WA, Coen KM (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171–176PubMedGoogle Scholar
  7. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proc Nat Acad Sci USA 85:5274–5278PubMedGoogle Scholar
  8. Fagerstrom K, Schneider NG (1989) Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 12:159–182CrossRefPubMedGoogle Scholar
  9. Farde L, Wiesel AJ, Nordstrom AL, Sedvall G (1989) D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:528–531CrossRefGoogle Scholar
  10. Feyerabend C, Russell MAH (1990) A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol 42:450–452PubMedGoogle Scholar
  11. Gawin FH (1986) Neuroleptic reduction of cocaine induced paranoia but not euphoria. Psychopharmacologia 90:142–143CrossRefGoogle Scholar
  12. Gunne LM, Angaard E, Jonsson LE (1972) Clinical trials with amphetamine-blocking drugs. Psychiatr Neurol Neurochir 75:225–226PubMedGoogle Scholar
  13. Haertzen CA, Hickey JE (1987) Addiction Research Centre Inventory (ARCI): measurement of euphoria and other drug effects. In: Bozarth MA (ed) Methods of assessing the reinforcing properties of abused drugs. Springer, New York Berlin HeidelbergGoogle Scholar
  14. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127PubMedGoogle Scholar
  15. Henningfield JE, Griffiths RR (1981) Cigarette smoking and subjective response: effects ofd-amphetamine. Clin Pharmacol Ther 30:497–505PubMedGoogle Scholar
  16. Hughes JR, Hatsukami DK (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294PubMedGoogle Scholar
  17. Jarvik M, Killen JD, Varady A, Fortman SP (1993) The favourite cigarette of the day. J Behav Med (in press)Google Scholar
  18. Jarvis M, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y (1984) Biochemical markers of smoke absorption and self-reported exposure to passive smoking. J Epidemiol Community Health 38:335–339PubMedGoogle Scholar
  19. Katz JL (1989) Drugs as reinforcers: pharmacological and behavioural factors. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward. Clarenden Press, OxfordGoogle Scholar
  20. Koob GF, Goeders NE (1989) Neuroanatomical substrates of drug self-administration. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward. Clarenden Press, OxfordGoogle Scholar
  21. Langone JJ, Van Vunakis H, Hill P (1975) Quantification of cotinine in sera of smokers. Res Commun Chem Pathol Pharmacol 10:21–28PubMedGoogle Scholar
  22. London ED, Casella NG, Wong DF, Phillips RL, Dannals RF, Links JM, Herning R, Grayson R, Jaffe JH, Wagner HN (1990) Cocaine-induced reduction of glucose utilisation in human brain. Arch Gen Psychiatry 47:567–574PubMedGoogle Scholar
  23. Nemeth-Coslett R, Henningfield JE, O'Keefe MK, Griffiths RR (1986) Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88:420–425CrossRefPubMedGoogle Scholar
  24. Nordstrom AL, Farde L, Hallin C (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106:433–438CrossRefPubMedGoogle Scholar
  25. Nurnberger J I, Simmons-Alling S, Kessler L, Jimerson S, Schreiber J, Hollander E, Tamminga CA, Nadi NS, Goldstein DS, Gershon ES (1984) Separate mechanisms for behavioral, cardiovascular and hormonal responses to dextroamphetamine in man. Psychopharmacology 84:200–204CrossRefPubMedGoogle Scholar
  26. Pomerleau CS, Pomerleau OF, Majchrzak MJ (1987) Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine levels. Psychopharmacology 91:391–393CrossRefGoogle Scholar
  27. Russell MAH (1987) Nicotine intake and its regulation by smokers. In: Martin WR, Van Loon GR, Iwamoto ET, Davis L (eds) Tobacco smoking and nicotine. Plenum, NewYorkGoogle Scholar
  28. Russell MAH, Peto J, Pate UA (1974) The classification of smoking by factorial structure of motives. J R Stat Soc 137:313–333Google Scholar
  29. Sherer MA, Kumor KM, Jaffe J (1989) Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 27:117–125CrossRefPubMedGoogle Scholar
  30. Stolerman IP, Goldfarb RF, Fink R, Jarvik ME (1973) Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 28:247–259CrossRefPubMedGoogle Scholar
  31. Taylor P (1980) Ganglionic stimulating and blocking agents. In: Gilman AG, Goodman LS (eds) The pharmacological basis of therapeutics, 6th edn. McMillan, New YorkGoogle Scholar
  32. Tiffany ST, Drobes DJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict 86:1467–1476PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • S. Dawe
    • 1
  • J. A. Gray
    • 1
  • M. A. H. Russell
    • 2
  • C. Gerda
    • 3
  1. 1.Psychology DepartmentInstitute of PsychiatryLondonUK
  2. 2.Health Behaviour UnitInstitute, of PsychiatryLondonUK
  3. 3.Hurley ClinicLondonUK

Personalised recommendations